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X-chromosome inactivation (XCI) is the process in
which females transcriptionally silence one of their
two X chromosomes in early embryonic development,
equalizing X chromosome gene expression between
males and females. XCI depends on a gene called
XIST, a functional RNA molecule that does not code
for a protein. Recent studies indicate abundant
intergenic transcription and nonprotein coding RNAs
in the human genome, which are suspected to
function in modulating gene expression. XCI may
therefore serve as a useful model to learn and
understand the potential function of these elements,
as well as their effects on human disease. Here, we
review the genetic and molecular basis of XCI and
describe how the mechanistics of this process lead to
the phenotypes of X-linked skin diseases, most
notably in the pattern of lines, swirls, and whorls first
noted by the dermatologist Alfred Blaschko. We
suggest that XCI, and other epigenetic phenomena,
will continue to impact our understanding of the
genetic mechanisms of disease.
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THE IMPORTANCE OF DOSAGE COMPENSATION
Humans are sensitive to chromosomal dosage. In the majority
of cases, developing fetuses that are either missing a
chromosome or are carrying an extra chromosome do not
survive to birth. Genetically, having an abnormal number of
chromosomes is known as aneuploidy. In the uncommon
cases where autosomal aneuploidies are viable, most notably
in trisomies 13, 18, and 21 (respectively known as the Patau,
Edwards, and Down syndromes), affected individuals display
serious congenital malformations. By contrast, aneuploidies
of the X chromosome are among the most common viable
chromosomal abnormalities, and whose affected individuals
can have relatively moderate phenotypes. The best known of
these include Turner syndrome (XO females) and Klinefelter
syndrome (XXY males). The reason that X chromosome
aneuploidies are better tolerated than autosomal aneu-
ploidies is due to the phenomenon of X-chromosome
inactivation (XCI), in which all X chromosomes are trans-
criptionally silenced except for one. Thus, females of all
sex karyotypes (XO, XX, XXX, or XXXX) will each have only
one active X chromosome with all supernumerary X’s being
inactivated. The genetic region that controls XCI is located
on the long arm of the X chromosome and is known as the
X-inactivation center.
THE X FACTOR: XIST RNA AND THE MOLECULAR
BASIS OF XCI
X-chromosome inactivation is initiated independently in each
cell during the blastocyst stage. The key initiating event
involves expression of a gene called the X-inactive specific
transcript or XIST (pronounced ‘‘exist’’) (Brown et al., 1992).
XIST has several unconventional properties. First, it is acti-
vated only in cells with more than one X, and therefore it is
not expressed in male cells. Second, XIST is expressed from
only one of the two X’s in females, randomly inactivating
either the maternal or paternal X chromosome. Third, the XIST
gene itself does not code for a protein, but instead appears to
function entirely as an RNA molecule. Finally, XIST RNA has
the characteristic of remaining exclusively nuclear, spreading
from its site of transcription to ‘‘coat’’ the X chromosome from
which it was produced. RNA fluorescence in situ hybridiza-
tion using probes for XIST shows a ‘‘cloud’’ of XIST RNA that
coats the inactive X chromosome (Figure 1a).
The expression and propagation of XIST RNA during
early development is both necessary and sufficient to trigger
long-range, chromosome-wide gene silencing across the
X chromosome. The mechanistic details of the silencing
cascade are not fully understood and are an area of intensive
study (Chow et al., 2005). The current evidence supports
a model in which the structural domains within XIST
RNA engage a variety of repressive transcriptional pathways
(Figure 2a). Genetic studies have shown, for instance, that
XIST RNA expression recruits the embryonic ectoderm
development/enhancer of Zeste homolog 2 protein complex
to the X-chromosome (Kohlmaier et al., 2004). Embryonic
ectoderm development/enhancer of Zeste homolog 2 is a
component of the Polycomb group of proteins that are critical
for setting up developmental patterns of gene expression
(Schuettengruber et al., 2007). They function in part by
chemically modifying histones—the structural proteins around
which DNA are spooled—making the associated DNA regions
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less accessible to transcription in a way that can be
maintained through future cell divisions.
The search continues to identify other factors that interact
with XIST RNA. Some candidate-interacting pathways have
not been formally proven but are thought to be likely. On the
inactive X chromosome, the cytosine nucleotides at gene
promoters are often methylated, an epigenetic process known
as promoter CpG island methylation. This chemical mod-
ification has been associated with durable gene silencing
(Jones and Takai, 2001). Along this line of reasoning, it is
likely that XIST recruits DNA methyltransferase proteins,
although the connection may be direct or indirect. Other
possibilities include other histone-modifying proteins with
gene-silencing activity, such as histone deacetylators and
histone methyltransferases. Together, these higher-order gene
control pathways cooperate to create multiple, redundant
mechanisms to assure that the inactive X remains silent
(Csankovszki et al., 2001). In humans, the inactive X is
recognized on the cytological level as the Barr body, which is
a dense cellular element reflective of the tight chromatin
packaging (Figure 1b).
There are several outstanding mysteries about XCI. It is still
unknown how the structural domains of this long RNA,
whose sequence is poorly conserved among mammals, is
able to trigger such a potent chromosome-wide process and
how it manages to only affect the chromosome from which it
is transcribed. The location of the inactive X chromosome
within the nucleus may be important: XIST appears capable
of bringing the X chromosome to a nuclear location that is
generally poor in RNA polymerases and transcription factors
(Chaumeil et al., 2006; Zhang et al., 2007). Another logistical
mystery is that of X-chromosome choice: how is a cell able
to ‘‘count’’ chromosomes and ‘‘choose’’ to inactivate one
chromosome but not the other? Recent developments provide
clues to this question, including the discovery that the two X
chromosomes seem to physically interact with each other just
before the triggering of XCI (Bacher et al., 2006; Xu et al.,
2006). This suggests, for example, that the two X chromo-
somes could transfer some mutually exclusive factor that
coordinates the expression of XIST from one X but not the
other.
Another exciting discovery, originally found in a mouse
model of XCI, is the presence of an antisense gene to mouse
Xist that is named Tsix (which is Xist spelled backward). As
the name implies, this gene is produced from the antisense
DNA strand from Xist and is transcribed through Xist in the
opposite direction (Lee et al., 1999) (Figure 2b). Genetic
evidence from mouse models indicates that Tsix represses
Xist expression in cis (Figure 2c). In a female cell, Tsix is
initially expressed on both X’s. During early development,
Tsix becomes turned off on one of the two X’s, which permits
the upregulation of Xist from that locus and leads to
inactivation of that chromosome. On the other X, Tsix
expression persists and ‘‘protects’’ that X chromosome from
expressing Xist and being inactivated. This sense–antisense
interplay resembles a molecular switch that directs the two X
chromosomes to opposite fates. Evidence suggests that Tsix
functions both as an RNA molecule as well as by altering the
Xist RNA X-paint H3-3mK27 Merge
Figure 1. The inactivated X chromosome. (a) XIST RNA fluorescence in situ
hybridization in a female somatic cell. RNA fluorescence in situ hybridization
with a probe against Xist RNA (green) shows a cloud of Xist RNA covering
the inactive X chromosome. The cell nucleus is counterstained with DAPI
(blue). Bar¼5 mm. (b) The Barr body in a female XX cell. In the left panel,
the X chromosomes of a female somatic cell are stained with a fluorescent
‘‘X paint’’ (green) and counterstained with DAPI (blue). In the middle panel,
a fluorescent antibody against histone 3 trimethylated at lysine
27—a heterochromatic marker—selectively designates the inactive
X chromosome, also known as the Barr body (red). In the right panel,
both images are merged. Bar¼ 5 mm.
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Figure 2. Molecular mechanism of XCI. (a) Schematic diagram of XCI. Before
inactivation, XIST is not expressed and the genes on the chromosome are
active. Upon expression of XIST, association of XIST RNA with cooperative
and redundant transcriptional silencing pathways serves to silence the
X chromosome in cis. After activation of XIST expression, the histones of the
X chromosome are deacetylated (represented by compaction of the histone
spheres), select histone lysine residues are methylated (represented by circles),
and promoter CpG islands are methylated (represented by closed lollipops).
Together, these factors lock the chromosome into an inactive state.
(b) Schematic diagram of mouse Xist/Tsix locus. In the mouse, an antisense
gene to Xist (black), named Tsix (gray), originates B12kb downstream of
the end of Xist and is transcribed through the entire Xist locus in the opposite
direction. Tsix functions to block Xist expression in cis. (c) Relationship of
Xist and Tsix RNAs in mouse XCI. Before the onset of X-inactivation, both
Xist (black dot) and Tsix (gray dot) are detectable at low levels on both
X chromosomes using fluorescence in situ hybridization, which is schematized
here in idealized form. At the onset of XCI, Tsix expression is turned off
on one of the two X’s, permitting the upregulation of Xist RNA from that
chromosome (black oval). On the other X, Tsix expression persists until Xist
is silenced. The chromosome expressing Xist becomes the inactive X (Xi),
whereas the chromosome that was protected by Tsix becomes the active X (Xa).
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Xist chromatin (Sado et al., 2005; Navarro et al., 2006; Sun
et al., 2006). It is notable that antisense expression has also
been detected downstream of human XIST and has been
named TSIX (Chow et al., 2003). It is tempting to speculate
that the antisense gene in humans plays a similar role as it
does in the mouse; however, this remains an area of debate
within the field (Migeon et al., 2002). Nonetheless, TSIX
represents one of the many antisense genes in the human
genome whose mechanism of action on gene expression and
disease will be an area of great interest in the coming years.
THE EXCEPTIONS TO THE RULES OF XCI, AND THEIR
CLINICAL IMPLICATIONS: SKEWED AND INCOMPLETE
X-INACTIVATION
X-chromosome inactivation is random in human embryonic
tissues, such that any given cell has a 50:50 chance of
choosing to inactivate the mother’s or father’s X chromo-
some. As a result, every female is a mosaic of cells, each
expressing exclusively her mother’s or father’s X-chromo-
some genes. However, several processes can occur that
disturb this randomness and lead to a predominance of
maternal or paternal expression, also known as ‘‘skewed
X-inactivation’’ (Figure 3a and b). As XCI begins when the
embryo consists of relatively few cells, it is stochastically
possible that some embryos will choose to inactivate
substantially more of the maternal or paternal X chromosome
simply by chance. Another possible mechanism is that
there may be genetic modifiers or polymorphisms that bias
the cell to choose a particular chromosome (Plenge et al.,
1997). This bias is known as primary nonrandom X-inacti-
vation, reflecting a disturbance to the process of randomness
itself. Third, and probably most commonly, skewed
X-inactivation can arise by a selection process: if one
X chromosome contains a gene or genes that confer a growth
advantage or disadvantage, then after many cell divisions,
the overall ratio of cells may favor the expression of one
or the other X. This is known as secondary nonrandom
X-inactivation, reflecting the preserved randomness of the
initial ‘‘choice’’ but with skewing because of downstream
selective effects.
From a clinical standpoint, skewed X-inactivation can
affect females who are heterozygous for X-linked gene
mutations. Classically, X-linked traits have been classified
as dominant or recessive, similar to autosomal traits. In
practice, however, a significant proportion of female hetero-
zygotes with X-linked recessive mutations display clinical
features of disease in a spectrum of penetrance and severity
(Dobyns et al., 2004). The blurred distinction between
dominant and recessive traits may stem from the difference
between heterozygotes of X-linked and autosomal mutations.
With the ‘‘all-or-none’’ molecular nature of X-inactivation, a
female heterozygote with an X-linked mutation hasB50% of
her cells producing only the mutant X-linked gene product
andB50% of her cells producing only the wild-type product
although ‘‘escape’’ can occur (see below). By contrast, every
cell in a female heterozygote with an autosomal mutation
transcribes both chromosome copies, such that each cell will
have a 50% dose of wild-type gene product. Despite the fact
that about half of the cells of X-linked heterozygotes express
only the mutant gene, female heterozygotes of X-chromo-
some mutations can display reduced disease penetrance and/
or severity compared with hemizygous males, indicating that
the cells expressing the wild-type gene can provide protec-
tion against the disease.
In this context, skewed X-inactivation can influence the
appearance and severity of X-linked traits in heterozygous
females if a higher proportion of cells choose to inactivate the
wild-type X chromosome (Migeon, 2006). XCI skewing has
been described in female heterozygotes with Duchenne
muscular dystrophy and hemophilia A, who display aspects
of muscle weakness or bleeding dysfunction that have been
linked with preferential expression of the mutant X (Yoshioka
et al., 1998; Renault et al., 2007). In these female hetero-
zygotes, the X-inactivation skewing seems to cluster in
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Figure 3. Skewed X chromosome inactivation. (a) Schematic of
X-chromosome choice. In each female cell, the maternal X (Xm) or
paternal X (Xp) may be ‘‘chosen’’ to be active. Before inactivation, both
Xm and Xp are active. XIST RNA (dotted line) is randomly selected to be
expressed from either the maternal X (top row, blue cells) or the paternal X
(bottom row, orange cells). XIST coats the chromosome from which it
is expressed and causes it to be transcriptionally silent and condensed.
(b) Models of skewed X-chromosome choice. In female mammals, each cell
independently chooses to inactivate either the maternal (blue) or paternal
(orange) X chromosome. Before XCI begins, each cell has two active Xs (gray).
In random XCI, cells choose either the maternal or paternal X in a B50:50
ratio (top row). With further development and cell division, the same ratio
is maintained. In primary nonrandom X-inactivation, some factor or
modification alters the random choice, such that either the maternal or
paternal X is preferentially chosen (middle row). In secondary nonrandom
X-inactivation, the initial choice of X-inactivation is still random, but a
gene on one or the other X chromosome favors the selection of the
cells containing either the maternal or paternal X. With further cell divisions,
the total number of cells is skewed toward those expressing the favored
X chromosome (bottom row).
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families, suggesting that there is an inherited locus that either
disturbs X-chromosome randomness or provides a selective
pressure against the other X chromosome. Therefore, if a
female heterozygote manifests clinical features of X-linked
disease that deviates in severity from what is expected, it is
worthwhile to examine her X-inactivation pattern (as well
as those of her female relatives) to determine if skewed
X-inactivation is involved.
In addition to skewed X-inactivation, a second ‘‘excep-
tion’’ to the rules of XCI is that not all X-chromosome genes
are silenced on the inactive X chromosome. A comprehen-
sive survey indicates thatB85% of all human X-linked genes
are silenced on the inactive X chromosome, but that
the remaining genes are either partially or fully expressed
(Carrel and Willard, 2005). These genes are referred to as
‘‘escape’’ genes, and are therefore expressed to at least some
extent from both X’s in female cells. One of the best-
characterized examples is the steroid sulfatase gene that is
mutated in X-linked ichthyosis (Hernandez-Martin et al.,
1999). In affected males, this disease results in a hyper-
keratosis from a failure to properly shed senescent keratino-
cytes. If the steroid sulfatase gene was subject to XCI, female
heterozygotes might be predicted to display a phenotype in
areas of skin choosing to inactivate the wild-type X chromo-
some. However, as the steroid sulfatase gene ‘‘escapes’’ XCI
and is expressed from both X chromosomes, the wild-type
gene product is present in all cells, protecting against the
clincal phenotype in female heterozygotes.
In summary, understanding the connection between
X-chromosome disease genotype and phenotype depends
on knowing the rules and exceptions of XCI.
BLASCHKO AND THE PATTERN OF X-LINKED
MOSAICISM IN SKIN DISEASE
As XCI is complete after the blastocyst stage, the manifesta-
tion of X-linked phenotypes depends largely on the way in
which these cells subsequently divide, mingle, and migrate to
form the organs of the body. Knowledge about the clonality
of different human organs is unfortunately incomplete;
however, current understanding of select human tissues
suggests significant variability: intestinal villi, for example,
appear to be polyclonal—in other words, they consist of a
heterogenous mixture of cells with either an active maternal
or paternal X chromosome (Thomas et al., 1988). Intestinal
crypts, by contrast, appear to be monoclonal in nature, with
large clusters of crypt cells expressing only the maternal or
paternal X. Further analysis of tissue clonality will aid future
understanding of X-linked disease on the molecular level
(Bittel et al., 2008).
Compared with many other tissues, the cutaneous mani-
festation of XCI mosaicism is better understood, thanks in part
to the visual phenotype of individuals who carry X-linked
mutations. These visual patterns are currently recognized as
the archetypal pattern described by the dermatologist Alfred
Blaschko, which has been subsequently updated by others
(Figure 4a). Blaschko was a private dermatology practitioner
who documented epidermal and sebaceous nevi with a
characteristic linear appearance on the extremities, S-shaped
curves on the trunk region, and V-shaped patterns on the
back. He noted that the pattern of the affected regions were
not the same as dermatomes, and were remarkably consistent
between different affected individuals. He proposed that
these lines might correspond to some sort of embryonic
event, although it was uncertain what that event might be
(Blaschko, 1901; Jackson, 1976). Many years later, Rudolf
Happle hypothesized that skin disorders following Blaschko’s
lines could be explained by the mosaicism that results from
XCI or early somatic mutations (Happle, 1985). Blaschko’s
lines therefore map out a migratory history of ectodermal skin
cells as they have proliferated and traveled from embryonic
Front Back
Figure 4. Patterns of X-linked skin disease. (a) Blaschko’s lines. The visual
appearance of X-linked skin disease can follow the pattern of lines described
by the dermatologist Alfred Blaschko. The archetypal figure has been
subsequently updated by others and is represented elsewhere with greater
detail in regions such as the head and neck (see Happle and Assim, 2001).
(b) Incontinentia pigmenti. The hyperpigmentation stage of incontinentia
pigmenti shows the characteristic whorled pattern that follow Blaschko’s
lines. Image used with permission from Dermatology, Vol. 1, Bolognia,
Jorizzo, and Rapini, Diseases of Hyperpigmentation, p. 996, Copyright 2003,
Elsevier. (c) Iodine starch test in female carrier of anhidrotic ectodermal
dysplasia. Application of starch in this female carrier shows a characteristic
‘‘fountain pattern’’ of dark areas with normal sweat glands as well as
light areas that have no sweat glands. Image used with permission from
Cambiaghi et al., Copyright 2000, American Medical Association.
All rights reserved.
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development into the fully formed organism, with alternating
affected and unaffected lines representing cells that have
inactivated either the normal or mutant X chromosome.
One of the best-studied examples of an X-linked disease
with a blaschkolinear pattern is incontinentia pigmenti
(OMIM 308300). This disease is caused by mutations to the
X-linked NF-kB essential modulator (NEMO) gene (Smahi
et al., 2000) and is lethal in males but has a variable
phenotype in female heterozygotes. As its name implies,
NEMO is a key regulator of the NF-kB signal transduction
pathway, an important genetic mediator of immune and
inflammatory responses. In female heterozygotes, vesicles
and bullae form in the distribution of Blaschko’s lines during
very early life; these lesions later progress to a verrucous
stage, which then give way to hyperpigmentation that
develops in characteristic whirls and streaks on the trunk
(Figure 4b). This hyperpigmentation often fades with time and
is gone by adulthood. A fourth stage can occur, which is
characterized by hypopigmented, atrophic lesions in a linear
pattern. In addition to lesions on the skin, other dermato-
logical manifestations of the disease include alopecia (which
can result in swirls of hairlessness on the scalp) and nail
dysplasias. Despite the varied skin changes that occur from
incontinentia pigmenti, the morbidity from the disease is
primarily due to effects of the NEMO mutation in the central
nervous, ocular, and musculoskeletal systems.
Female heterozygotes with NEMO mutations have been
observed to display variability in the severity of their
phenotypes. One might predict that the relative ratios of
mutant-to-normal X chromosome inactivation would corre-
late to the severity of disease. Consistent with this, skewed
X-inactivation that favors inactivation of the mutant
X chromosome has been observed in female heterozygotes,
suggesting that secondary nonrandom X-inactivation can
occur because of the presumptive growth advantage of the
normal cell over the NEMO-mutant cell (Martinez-Pomar
et al., 2005). This secondary selection is also thought to be
responsible for the resolution of skin lesions in later in the life
of affected females (Nelson, 2006). Of the rare viable males
with the disease, some have been shown to have Klinefelter
syndrome (XXY) and are therefore protected from the lethal
phenotype by the presence of a wild-type second X
chromosome (Kenwrick et al., 2001). In these observations,
it is clear that the clinical presentation of incontinentia
pigmenti illustrates the genetic principles of XCI.
Over a dozen other X-linked conditions have been
described that follow the cutaneous patterns described by
Blaschko (Table 1, footnote 1). These include anhidrotic
ectodermal dysplasia (OMIM 305100), a disease caused by
mutation in the X-linked ectodysplasin A (EDA) gene, which
can result in patches of skin that contain no sweat glands. Use
of an iodine starch test in female heterozygotes, which causes
a violet-colored darkening of areas containing sweat glands,
produces a striking visual demonstration of Blaschko’s lines
(Figure 4c), with a clear demarcation between affected and
unaffected areas. Other X-linked cutaneous genetic diseases
include oral–facial–digital syndrome type I, in which affected
girls have spirals of hairlessness on the scalp; X-linked
Table 1. X-linked conditions with skin manifestations
Condition OMIM no.
Adrenal hypoplasia, congenital 300200
Adrenoleukodystrophy 300100
Albinism–deafness syndrome 300700
Alport syndrome X-linked 301050
Amyloidosis, familial cutaneous (pigmentary disorder,
reticulate with systemic manifestations)1
301220
Androgen insensitivity syndrome 300068
Angelman syndrome 105830
Angioma serpiginosum, X-linked1 300652
Bazex syndrome 301845
CHILD syndrome (congenital hemidysplasia with
ichthyosiform erythroderma and limb defects)1
308050
Chondrodysplasia punctata (Conradi–Hunerman–Happle
syndrome)1
302960
Chondrodysplasia punctata (XLR) 302950
Chronic granulomatous disease, X-linked 306400
Coffin–Lowry syndrome 303600
Craniofrontonasal syndrome 304110
Cutis laxa X-linked/Occipital Horn syndrome 304150
Dyskeratosis congenita, X-linked1 305000
Ectodermal dysplasia (anhidrotic)1 305100
Ectodermal dysplasia, hypohidrotic with immune deficiency1 300291
Ehlers–Danlos variant, heterotopia, periventricular 300537
Epidermolysis bullosa, macular type 302000
Fabry disease 301500
Fanconi pancytopaenia B 300514
Opitz-Kaveggia syndrome 305450
Goltz syndrome (focal dermal hypoplasia)1 305600
Ichthyosis, X-linked 308100
Ichthyosis follicularis, atrichia, and photophobia syndrome1 308205
Immunodysregulation, polyendocrinopathy, and enteropathy,
X-linked
304790
Incontinentia pigmenti1 308300
Keratosis follicularis spinulosa decalvans 308800
Lesch–Nyhan syndrome 300322
Lowe oculocerebrorenal-syndrome 309000
Melnick–Needles syndrome 309350
Menkes syndrome1 309400
Midas syndrome (microphthalmia, dermal aplasia, and
sclerocornea)1
309801
Orofaciodigital syndrome I1 311200
Simpson–Golabi–Behmel syndrome type 1 312870
Simpson–Golabi–Behmel syndrome type 2 300209
Terminal osseous dysplasia and pigmentary defects 300244
Torticollis, keloids, cryptochidism, and renal dysplasia 314300
Wiskott–Aldrich syndrome 301000
1Condition manifests in Blaschko’s lines.
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chondrodysplasia punctata (Conradi–Hunerman–Happle
syndrome), which results in linear and whorled patterns
of pigmentary and atrophic lesions; and focal dermal hypo-
plasia, a disease that can also display linear patterns of
hyperpigmentation and skin atrophy.
To date, over 300 X-chromosome genetic loci have been
linked to disease (please refer to the National Center for
Biotechnology Information’s reference link to genes and
disease at http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=gnd).
A significant number of these X-linked conditions have skin
manifestations as a significant or predominant component
(Table 1).
HOW WILL EPIGENETIC MECHANISMS INFLUENCE
OUR UNDERSTANDING OF DISEASE?
Although XCI has been known for over 50 years, the
implications of this phenomenon on disease continues to
emerge. Recently, the first tumor suppressor gene that
resides on the X chromosome, WTX, was identified as a
significant genetic cause of Wilm’s tumor (Rivera et al.,
2007). In addition to the traditional genetic considerations,
the location of this gene on the X chromosome immediately
raised epigenetic questions as well. Tumor suppressor genes
are thought to follow Knudson’s two-hit hypothesis, which
postulates that both tumor suppressor genes must be ‘‘hit’’
by mutation to lead to tumor formation. With one active
X chromosome in both males and females, one would
anticipate that both sexes can only sustain one WTX hit.
On the other hand, one might speculate that females are
better suited to tolerate WTX somatic mutations if the
mutations ‘‘hit’’ the inactive WTX allele half of the time.
Interestingly enough, however, no male bias for Wilm’s
tumor is seen in the data (Huff, 2007). The example of
WTX illustrates how X-inactivation continues to impact
our understanding and interpretation of new genetic
discoveries.
The lessons learned from X-inactivation may soon extend
beyond the realm of X chromosome genes. Until recently,
genes that are active only on the maternally or paternally
inherited chromosome—an expression pattern known as
monoallelic expression—were thought to be limited to
X-linked and imprinted genes, as well as specialized genes
such as the odorant receptors. However, a recent genome-
wide sample suggests that B5% of autosomal genes may
be monoallelically expressed (Gimelbrant et al., 2007). The
investigators extrapolate from their study to suggest that up to
1,000 human autosomal genes may feature monoallelic
expression, with a cell-by-cell random choice of maternal or
paternal expression. Some of the genes identified in the study
are known to be connected with human disease, prompting
important future questions to understand how this XCI-like
expression pattern may influence disease phenotypes. The
lessons learned from the paradigm of X-inactivation, includ-
ing the concepts of all-or-none expression, random choice of
expression between the two inherited chromosomes, as well
as primary versus secondary selection effects, may soon
prove to be applicable to the understanding of a significant
subset of autosomal genes as well.
The recent sequencing of the human genome and
continued discoveries from genome-wide analysis represent
only the beginning of our understanding of genetic disease.
The building blocks provided by the completed genome
sequence will allow for the study of more complex, multi-
factorial, and epigenetic effects on disease phenotypes. The
unique visual nature of skin disease provides a valuable stage
where these genotypes and phenotypes will be directly seen
and studied for years to come.
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